Head to head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD

Two-step strategy, FIB-4 followed by magnetic resonance elastography, for detecting advanced fibrosis in NAFLD

(2022) Nobuharu Tamaki et al.   Clinical Gastroenterology and Hepatology

Impact of non-invasive biomarkers on hepatology practice: Past, present and future

(2022) Quentin M. Anstee et al.   JOURNAL OF HEPATOLOGY

Current therapies and new developments in NASH

(2022) Jean-François Dufour et al.   GUT

Comorbidities and healthcare costs and resource use of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the Japan medical data vision database

(2021) Shuji Terai et al.   JOURNAL OF GASTROENTEROLOGY

Mechanisms and disease consequences of nonalcoholic fatty liver disease

(2021) Rohit Loomba et al.   CELL

Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease

(2021) Fasiha Kanwal et al.   GASTROENTEROLOGY

KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease

(2021) Seong Hee Kang et al.   Clinical and Molecular Hepatology

Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD

(2021) Nobuharu Tamaki et al.   Nature Reviews Endocrinology

FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study

(2020) Philip N Newsome et al.   Lancet Gastroenterology & Hepatology

Cost Effectiveness of Different Strategies for Detecting Cirrhosis in Patients With Non-alcoholic Fatty Liver Disease Based on United States Health Care System

(2020) Eduardo Vilar-Gomez et al.   Clinical Gastroenterology and Hepatology

Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial

(2020) Rohit Loomba et al.   Lancet Gastroenterology & Hepatology

Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH

(2020) Theresa J. Hydes et al.   Clinical and Molecular Hepatology

Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease

(2020) Kyung-Soo Kim et al.   Clinical and Molecular Hepatology

Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology

(2020) Silvia Sookoian et al.   Clinical and Molecular Hepatology

MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis

(2020) Jinho Jung et al.   GUT

Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention

(2020) Daniel Q. Huang et al.   Nature Reviews Gastroenterology & Hepatology

Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective

(2020) Gwyneth Soon et al.   Clinical and Molecular Hepatology

Agreement and Reproducibility of Proton Density Fat Fraction Measurements Using Commercial MR Sequences Across Different Platforms

(2019) Jong Keon Jang et al.   INVESTIGATIVE RADIOLOGY

Prospective, Same-day, Direct Comparison of CAP With the M vs the XL Probe in Patients With Nonalcoholic Fatty Liver Disease, Using Magnetic Resonance Imaging Proton Density Fat Fraction as the Standard

(2019) Cyrielle Caussy et al.   Clinical Gastroenterology and Hepatology

ROC and AUC with a Binary Predictor: a Potentially Misleading Metric

(2019) John Muschelli   JOURNAL OF CLASSIFICATION

Non-Invasive Diagnosis of Nonalcoholic Fatty Liver Disease

(2018) Masato Yoneda et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Magnetic Resonance vs Transient Elastography Analysis of Patients With Non-alcoholic Fatty Liver Disease: a Systematic Review and Pooled Analysis of Individual Participants

(2018) Cynthia Hsu et al.   Clinical Gastroenterology and Hepatology

Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers

(2018) Eduardo Vilar-Gomez et al.   JOURNAL OF HEPATOLOGY

Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease

(2017) Charlie C. Park et al.   GASTROENTEROLOGY

Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis

(2017) Guangqin Xiao et al.   HEPATOLOGY

Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis

(2017) Parambir S. Dulai et al.   HEPATOLOGY

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

(2017) Zobair Younossi et al.   Nature Reviews Gastroenterology & Hepatology

Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis

(2016) Stuart McPherson et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography

(2016) Kento Imajo et al.   GASTROENTEROLOGY

Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease

(2016) Jérôme Boursier et al.   JOURNAL OF HEPATOLOGY

Multisite, multivendor validation of the accuracy and reproducibility of proton-density fat-fraction quantification at 1.5T and 3T using a fat-water phantom

(2016) Diego Hernando et al.   MAGNETIC RESONANCE IN MEDICINE

Liver Stiffness Measurements with MR Elastography: Agreement and Repeatability across Imaging Systems, Field Strengths, and Pulse Sequences

(2016) Andrew T. Trout et al.   RADIOLOGY

Ezetimibe for the treatment of nonalcoholic steatohepatitis: Assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial)

(2015) Rohit Loomba et al.   HEPATOLOGY

Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up

(2015) Mattias Ekstedt et al.   HEPATOLOGY

The global NAFLD epidemic

(2013) Rohit Loomba et al.   Nature Reviews Gastroenterology & Hepatology

Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics

(2012) Y Kanda   BONE MARROW TRANSPLANTATION

pROC: an open-source package for R and S+ to analyze and compare ROC curves

(2011) Xavier Robin et al.   BMC BIOINFORMATICS